JP2021523717A - 代謝、生存、および機能を促進するための免疫細胞におけるarid5b発現の操縦 - Google Patents
代謝、生存、および機能を促進するための免疫細胞におけるarid5b発現の操縦 Download PDFInfo
- Publication number
- JP2021523717A JP2021523717A JP2020564104A JP2020564104A JP2021523717A JP 2021523717 A JP2021523717 A JP 2021523717A JP 2020564104 A JP2020564104 A JP 2020564104A JP 2020564104 A JP2020564104 A JP 2020564104A JP 2021523717 A JP2021523717 A JP 2021523717A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- arid5b
- cell
- expression
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670962P | 2018-05-14 | 2018-05-14 | |
| US62/670,962 | 2018-05-14 | ||
| PCT/US2019/031296 WO2019221991A1 (en) | 2018-05-14 | 2019-05-08 | Manipulating arid5b expression in immune cells to promote metabolism, survival, and function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523717A true JP2021523717A (ja) | 2021-09-09 |
| JP2021523717A5 JP2021523717A5 (cg-RX-API-DMAC7.html) | 2022-05-17 |
Family
ID=68540927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564104A Pending JP2021523717A (ja) | 2018-05-14 | 2019-05-08 | 代謝、生存、および機能を促進するための免疫細胞におけるarid5b発現の操縦 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12109236B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3793574A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021523717A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112888446A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019269318A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3100312A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019221991A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7793517B2 (ja) * | 2019-11-28 | 2026-01-05 | アムニオティクス・アーベー | ソース細胞から決定的造血細胞を生成する方法 |
| CN111733154B (zh) * | 2020-04-30 | 2022-11-04 | 和也健康科技有限公司 | 磁场处理的免疫细胞及其用途 |
| KR20230042671A (ko) * | 2020-05-28 | 2023-03-29 | 바이오마그네틱 솔루션스 엘엘씨 | 단일 항체를 이용한 나이브 t 및 b 세포의 음성 선택을 위한 조성물 및 방법 |
| EP4419541A4 (en) * | 2021-10-21 | 2025-12-17 | Univ Texas | METHOD FOR PRODUCING THERAPEUTIC IMMUNE CELLS WITH IMPROVED METABOLIC FITNESS AND COMPOSITIONS THEREOFUL |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017048809A1 (en) * | 2015-09-14 | 2017-03-23 | Regents Of The University Of Minnesota | Nk cells exhibiting an adaptive phenotype and methods for preparing and for using |
| WO2017112877A1 (en) * | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837492A (en) | 1995-12-18 | 1998-11-17 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
| US6448717B1 (en) | 2000-07-17 | 2002-09-10 | Micron Technology, Inc. | Method and apparatuses for providing uniform electron beams from field emission displays |
| US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| EP3452580B1 (en) | 2016-05-02 | 2023-08-16 | Cerus Corporation | Compositions and methods for improved nk cell therapies |
-
2019
- 2019-05-08 CA CA3100312A patent/CA3100312A1/en active Pending
- 2019-05-08 AU AU2019269318A patent/AU2019269318A1/en not_active Abandoned
- 2019-05-08 US US17/055,525 patent/US12109236B2/en active Active
- 2019-05-08 JP JP2020564104A patent/JP2021523717A/ja active Pending
- 2019-05-08 EP EP19803724.4A patent/EP3793574A4/en not_active Withdrawn
- 2019-05-08 WO PCT/US2019/031296 patent/WO2019221991A1/en not_active Ceased
- 2019-05-08 CN CN201980046610.6A patent/CN112888446A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017048809A1 (en) * | 2015-09-14 | 2017-03-23 | Regents Of The University Of Minnesota | Nk cells exhibiting an adaptive phenotype and methods for preparing and for using |
| WO2017112877A1 (en) * | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
Non-Patent Citations (1)
| Title |
|---|
| GENES & DEVELOPMENT, vol. Vol.31, No.23-24, JPN6023015475, 2017, pages 2343 - 2360, ISSN: 0005041670 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210154232A1 (en) | 2021-05-27 |
| AU2019269318A1 (en) | 2021-01-07 |
| EP3793574A4 (en) | 2022-03-09 |
| EP3793574A1 (en) | 2021-03-24 |
| WO2019221991A1 (en) | 2019-11-21 |
| CN112888446A (zh) | 2021-06-01 |
| CA3100312A1 (en) | 2019-11-21 |
| US12109236B2 (en) | 2024-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ruella et al. | Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies | |
| Hatae et al. | Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment | |
| CN112386680B (zh) | 在胃肠道移植物抗宿主病的治疗中使用il-22的方法 | |
| JP6858128B2 (ja) | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ | |
| JP2021119197A (ja) | 癌治療のための併用免疫療法及びサイトカイン制御療法 | |
| JP2022520402A (ja) | 免疫療法のための改変ナチュラルキラー(nk)細胞 | |
| Lee et al. | Tissue resident Foxp3+ regulatory T cells: sentinels and saboteurs in health and disease | |
| Talker et al. | Monocyte biology conserved across species: Functional insights from cattle | |
| US20250333764A1 (en) | Engineered regulatory t cells | |
| US12109236B2 (en) | Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function | |
| JP2024520676A (ja) | Nr4a3欠損免疫細胞及びその使用 | |
| KR20220061148A (ko) | 세포 노화 조절 방법 및 조성물 | |
| Ellert-Miklaszewska et al. | 7aaRGD-a novel SPP1/integrin signaling-blocking peptide reverses immunosuppression and improves anti-PD-1 immunotherapy outcomes in experimental gliomas | |
| US20250011764A1 (en) | In vivo crispr screening system for discovering therapeutic targets in cd8 t cells | |
| TW202600814A (zh) | γδT細胞組合物及使用方法 | |
| Cunha et al. | Infiltration of tumors is regulated by T cell–intrinsic nitric oxide synthesis | |
| US9376663B2 (en) | GPR15-mediated homing and uses thereof | |
| CN107073079A (zh) | 包括给予PPAR‑γ激动剂的治疗癌症的方法 | |
| HK40044945A (en) | Manipulating arid5b expression in immune cells to promote metabolism, survival, and function | |
| WO2026063501A1 (en) | Method of enhancing anti-tumor response activity of t cell, method for treating tumor, t cell having enhanced anti-tumor response activity, and pharmaceutical composition | |
| Ellert-Miklaszewska et al. | Integrin blocking peptide reverses immunosuppression in experimental gliomas and improves anti-PD-1 therapy outcome | |
| US20250381273A1 (en) | Augmenting Mitochondria in Immune Cells for Improved Cancer Immunotherapy | |
| Herek et al. | Using Murine Models to Investigate Tumor–Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma | |
| US20230338423A1 (en) | Targetable immune checkpoint for immunotherapy | |
| WO2023237754A2 (en) | Cyclosporin h and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220506 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220506 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230420 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231109 |